Author

R. Genolet

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Assay:proteomics· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Organism:chicken / avian· 1 Research Focus:clustering· 1

Frequent Co-Authors

A. Harari· 3 shared C. Sauvage· 2 shared G. Coukos· 2 shared J. Schmidt· 2 shared L. Queiroz· 2 shared M. Bassani-Sternberg· 2 shared S. Bobisse· 2 shared A. Auger· 1 shared

Activity by Year

2022-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

A. Harari

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

KIR3DL1 and Tox identify clonally expanded encephalitogenic neuron-specific CD8+ T cells in autoimmune encephalitis

S. Perriot, S. Jones, R. Genolet, A. Mathias, H. Lindsay, S. Bobisse, G. Di Liberto, M. Canales, L. Queiroz, C. Sauvage, I. Wagner, L. Oberholster, M. Gimenez, D. Begarie, M. Theaudin, , R. Du Pasquier

The paper identifies clonally expanded neuron-specific CD8+ T cells in anti-Ri AIE patients using an unbiased approach and shows they express KIR3DL1 and TOX.

bioRxiv · Mar 25, 2024 · PreprintImmunology

Tumor-reactive clonotype dynamics underlying clinical response to TIL therapy in melanoma

J. Chiffelle, D. Barras, R. Petremand, A. Orcurto, S. Bobisse, M. Arnaud, A. Auger, B. Navarro Rodrigo, E. Ghisoni, C. Sauvage, D. Saugy, A. Michel, B. Murgues, N. Fahr, M. Imbimbo, , G. Coukos

This study tracks tumor-reactive TIL clonotypes in melanoma patients before and after TIL-ACT to identify factors associated with clinical response.

bioRxiv · Jul 21, 2023 · PreprintCancer Biology

Machine learning predictions of MHC-II specificities reveal alternative binding mode of class II epitopes

J. Racle, P. Guillaume, J. Schmidt, J. Michaux, A. Larabi, K. Lau, M. A. S. Perez, G. Croce, R. Genolet, G. Coukos, V. Zoete, F. Pojer, M. Bassani-Sternberg, A. Harari, D. Gfeller

The paper predicts MHC-II epitope specificities using machine learning, revealing a reverse binding mode in ligands across multiple species.

bioRxiv · Jun 26, 2022Immunology